Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CPA1 | P15085 | 6/20 | 0.58 |
| ▸ | CPA3 | P15088 | 3/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.58 |
| ▸ | CPB1 | P15086 | 1/20 | 0.58 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.58 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.53 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25187228 | 0.91 | CYP1A2 (0.55) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL1832075 | 0.84 | PPARG (0.55) | CYP1A2PPARGANPEP | |
| SCHEMBL12188594 | 0.84 | CYP1A2 (0.63) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL7293687 | 0.83 | SMN1; SMN2 (0.50) | CYP1A2ANPEP | |
| SCHEMBL27356033 | 0.81 | SMN1; SMN2 (0.48) | CYP1A2CPA3SLC1A1PPARGANPEP | |
| SCHEMBL4664822 | 0.80 | CYP1A2 (1.00) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL17995281 | 0.80 | CYP1A2 (0.68) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL6127015 | 0.79 | ALDH1A1 (0.52) | — | |
| SCHEMBL22115491 | 0.78 | CYP1A2 (0.95) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL9622038 | 0.78 | CYP1A2 (0.86) | CYP1A2CPA1CPA3FOLH1CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070924-A1 | Novel Formulations For Opioid-Based Treatments Of Pain Comprising 1-(1,2-Disubstituted Piperidinyl)-4-Substituted Piperazine Derivatives | JANSSENS FRANS EDUARD | 2008-03-20 | — | — | US | disclosed |
| EP-1635833-A1 | COMBINATIONS FOR OPIOID-BASED TREATMENT OF PAIN COMPRISING 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004110451-A1 | COMBINATIONS FOR OPIOID-BASED TREATMENT OF PAIN COMPRISING 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-23 | — | — | WO | disclosed |
| US-6521621-B1 | Tachykinin antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-02-18 | — | — | US | disclosed |
| US-6197772-B1 | TACHYKININS ANTAGONIST; ANTIINFLAMMATION AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-03-06 | — | — | US | disclosed |
| EP-0862566-B1 | 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2000-01-12 | — | — | EP | disclosed |
| EP-0862566-A1 | 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-09-09 | — | — | EP | disclosed |
| WO-1997016440-A1 | 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070924-A1 | Novel Formulations For Opioid-Based Treatments Of Pain Comprising 1-(1,2-Disubstituted Piperidinyl)-4-Substituted Piperazine Derivatives | OPRL1, OPRK1, OPRM1 | CYP1A2 409/4885CPA1 558/4885CPA3 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.